KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Equity Average (2016 - 2025)

Biogen has reported Equity Average over the past 17 years, most recently at $9.2 billion for Q4 2025.

  • Quarterly results put Equity Average at $9.2 billion for Q4 2025, down 44.65% from a year ago — trailing twelve months through Dec 2025 was $9.2 billion (down 44.65% YoY), and the annual figure for FY2025 was $17.5 billion, up 10.97%.
  • Equity Average for Q4 2025 was $9.2 billion at Biogen, up from $8.8 billion in the prior quarter.
  • Over the last five years, Equity Average for BIIB hit a ceiling of $17.3 billion in Q2 2025 and a floor of $8.8 billion in Q3 2025.
  • Median Equity Average over the past 5 years was $13.3 billion (2022), compared with a mean of $13.2 billion.
  • Biggest five-year swings in Equity Average: increased 22.52% in 2023 and later crashed 45.16% in 2025.
  • Biogen's Equity Average stood at $10.9 billion in 2021, then grew by 19.75% to $13.1 billion in 2022, then increased by 11.94% to $14.6 billion in 2023, then increased by 12.96% to $16.5 billion in 2024, then crashed by 44.65% to $9.2 billion in 2025.
  • The last three reported values for Equity Average were $9.2 billion (Q4 2025), $8.8 billion (Q3 2025), and $17.3 billion (Q2 2025) per Business Quant data.